Payment overview · 2025
General Payments
$856.11
56 reported records · 10 companies
Healthcare provider profile · identity verified
Abigail Joan Eubank, MSN, GNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · HENDERSONVILLE, TN · NPI 1588861207
Verified facts
What the public records show
CMS Open Payments records show Abigail Joan Eubank, MSN, GNP received $856.11 in general payments during 2025 across 56 reported records.
ABBVIE INC. accounted for 30.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Mounjaro, Ozempic, Qulipta, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $257.91 | 30.1% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $172.52 | 20.1% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.08 | 9.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.36 | 9.8% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $70.97 | 8.3% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $61.26 | 7.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.05 | 7.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.35 | 3.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.26 | 2.4% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $14.35 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $856.11 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $151.76 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $117.68 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $88.91 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $85.08 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $85.08 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $70.97 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $68.96 | 9 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $61.26 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.52 | 5 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $41.85 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $37.82 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.04 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.39 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $28.40 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $28.35 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 254 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 236 | 61 |
| Alprazolam | Alprazolam | 201 | 28 |
| Lisinopril | Lisinopril | 187 | 55 |
| Montelukast Sodium | Montelukast Sodium | 187 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 158 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 43 |
| Omeprazole | Omeprazole | 141 | 41 |
| Ozempic | Semaglutide | 120 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 14 |
| Metformin Hcl | Metformin Hcl | 102 | 32 |
| Gabapentin | Gabapentin | 99 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 38 |
| Losartan Potassium | Losartan Potassium | 95 | 29 |
| Trazodone Hcl | Trazodone Hcl | 93 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 23 |
| Azithromycin | Azithromycin | 77 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 30 |
| Simvastatin | Simvastatin | 76 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 21 |
| Clonazepam | Clonazepam | 70 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 70 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 21 |
| Lorazepam | Lorazepam | 68 | 12 |
| Famotidine | Famotidine | 64 | 23 |
| Xarelto | Rivaroxaban | 62 | 11 |
| Fluconazole | Fluconazole | 61 | 22 |
| Glimepiride | Glimepiride | 58 | 16 |
| Sertraline Hcl | Sertraline Hcl | 57 | 18 |
| Synthroid | Levothyroxine Sodium | 57 | 11 |
| Dexamethasone | Dexamethasone | 53 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 21 |
| Meloxicam | Meloxicam | 51 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 26 |
| Ezetimibe | Ezetimibe | 50 | 13 |
| Bupropion Xl | Bupropion Hcl | 46 | 13 |
| Donepezil Hcl | Donepezil Hcl | 46 | 16 |
| Carvedilol | Carvedilol | 45 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 13 |
| Pregabalin | Pregabalin | 45 | suppressed |
| Eliquis | Apixaban | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Potassium Chloride | Potassium Chloride | 40 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 19 |
| Furosemide | Furosemide | 39 | 14 |
| Allopurinol | Allopurinol | 38 | 12 |
| Alendronate Sodium | Alendronate Sodium | 37 | 17 |
| Ondansetron Odt | Ondansetron | 37 | 19 |
| Cephalexin | Cephalexin | 36 | 20 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 11 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 21 |
| Temazepam | Temazepam | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 19 |
| Nystatin | Nystatin | 28 | 20 |
| Valacyclovir | Valacyclovir Hcl | 28 | 15 |
| Belsomra | Suvorexant | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Prednisone | Prednisone | 23 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 18 |
| Irbesartan | Irbesartan | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 17 |
| Cefdinir | Cefdinir | 16 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 11 |
| Gemtesa | Vibegron | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $856.11 · 56 records | ABBVIE INC. | BREZTRI, GEMTESA, KISUNLA, Korlym, LEQVIO, MOUNJARO, NERLYNX, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, SYNTHROID, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error